Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis.
Acute kidney injury
Biomarkers
Cirrhosis
Hepatorenal syndrome
Liver transplantation
Terlipressin
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
entrez:
11
4
2021
pubmed:
12
4
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
Acute kidney injury (AKI) is a frequent complication in patients with cirrhosis. Patients with cirrhosis can develop AKI due to different causes. Hepatorenal syndrome (HRS) is a unique cause of AKI occurring in patients with advanced cirrhosis and is associated with high short-term mortality. The differential diagnosis between different causes of AKI may be challenging. In this regard, new urine biomarkers may be helpful. Liver transplantation is the definitive treatment of patients with HRS-AKI. Vasoconstrictors and albumin represent the first-line pharmacologic treatment of HRS-AKI. This review summarizes current knowledge for the diagnosis and management of HRS in cirrhosis.
Identifiants
pubmed: 33838860
pii: S1089-3261(21)00011-8
doi: 10.1016/j.cld.2021.01.011
pii:
doi:
Substances chimiques
Vasoconstrictor Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-460Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures Authors have nothing to disclose.